Recent findings suggest that the ovarian renin-angiotensin system regulates ovarian function through the paracrine/autocrine actions of angiotensin (Ang) II. The aims of this study were to investigate 1) the endothelial cell capacity to convert Ang I to Ang II, 2) the effects of endocrine and paracrine/autocrine factors on Ang II production in microvascular endothelial cells (MVE) derived from the developing corpora lutea (CL), and 3) the relationship between Ang II peptide concentration and expression of mRNA for angiotensin type 1 and 2 receptors (ATR1 and AT2R) in the bovine CL at different stages of the estrous cycle.
INTRODUCTION
It is known that the renin-angiotensin system (RAS) plays physiological roles in the female reproductive system 1 This study was supported by a Grant-in-Aid for Scientific Research (C) and the Japan-Germany joint research project of the Japan Society for the Promotion of Science, the Novartis Foundation (Japan) for the Promotion of Science (A.M.), and the German Research Foundation (Scha 257/14-1). K.H. was supported by H. Wilhelm Schaumann-Stiftung, and A.M. was supported by Alexander von Humbolt Stiftung. 2 Correspondence. FAX: 49 8161 714204; e-mail: physio@pollux.weihenstephan.de in several mammals. Components of this local RAS have been identified in the ovaries of a number of species. There is evidence that the biologically active form of angiotensin, angiotensin (Ang) II, regulates various ovarian functions such as oocyte maturation [1, 2] , follicular rupture [1, 2] , and steroidogenesis [3] . This vasoactive peptide, Ang II, is converted from Ang I by angiotensin-converting enzyme (ACE). Ang I is produced from the precursor angiotensinogen by the enzymatic activity of renin. In cattle, theca cells have been identified as a major source of ovarian prorennin [4, 5] , and as the sites of Ang II binding [6] .
By using an in vitro microdialysis system (MDS) implanted in bovine luteal explants from the midluteal phase of the estrous cycle, we have recently shown that Ang II decreases progesterone (P 4 ) release and that Ang II release is stimulated by prostaglandin (PG) F 2␣ [7] . These results suggest that the luteolytic effect of PGF 2␣ may be partly mediated by Ang II. In addition, it has been also reported that luteal endothelin-1 (ET-1), another vasoactive peptide produced in microvascular endothelial cells (MVE), has a local luteolytic action that is similar to those of Ang II in the bovine corpus luteum (CL) [8, 9] . ACE was predominantly localized in bovine pulmonary artery endothelial cells [10] , and Ang II receptors were localized in bovine aortic endothelial cells [11] , indicating that endothelial cells are the principal sites of the Ang II production and action in cattle. Moreover, Ang II has been shown to stimulate the expression of mRNA for a powerful angiogenic factor, basic fibroblast growth factor (bFGF), in bovine luteal cells [12] , and to stimulate the growth of bovine aortic endothelial cells [13] . These findings suggest that Ang II may also regulate angiogenesis in the developing CL. All these results indicate that vascular endothelial cells, which account for up to 50% of the bovine CL [14, 15] , may play essential roles by releasing vasoactive peptides in the CL function.
The aim of this study was, therefore, to investigate the possible physiological importance of Ang II by studying basic regulation of Ang II in MVE and CL by examining 1) the cell capacity to convert Ang I to Ang II, 2) the effects of endocrine and paracrine/autocrine factors on Ang II production in MVE derived from the developing CL, and 3) the relationship between Ang II peptide concentration and expression of mRNA for angiotensin type 1 and 2 receptors (AT1R and AT2R) in the bovine CL at different stages of the estrous cycle.
MATERIALS AND METHODS

Reagents
Dulbecco's modified Eagle's medium (DMEM)/nutrient mixture and Ham's F-12 (1:1), amphotericin B, gentamicin, transferrin, sodium selenite, arachidonic acid, P 4 , estradiol-17␤ (E 2 ), PGF 2␣ , PGE 2 , atrial natriuretic peptide, Ang I, and captopril were from Sigma (St. Louis, MO); fetal calf serum was from Biochrom (Berlin, Germany); collagen type I (Vitrogen 100) was from Collagen Corporation (Fremont, CA); ET-1 and oxytocin (OT) were from Peninsula Laboratories (Merseyside, UK); insulin and protease inhibitors (Complete tablets) were from Boehringer Mannheim (Mannheim, Germany); bovine LH (USDA bLH-B-5) was kindly provided by the USDA Animal Hormone Program (Beltsville, MD); bFGF was from Pepro (Frankfurt am Main, Germany); vascular endothelial growth factor (VEGF recombinant bovine) was from Dr. D. Gospodarowicz, Chiron Corp. (Oakland, CA); Trizol reagent was from Gibco BRL (Gaithersburg, MD); and thermostable polymerase PrimeZyme was from Biometra (Göttingen, Germany).
Endothelial Cell Culture
Microvascular endothelial cells (type III) isolated from developing bovine CL (Days 1-10) were kindly provided by Dr. K. Spanel-Borowski (University of Leipzig, Germany). The phenotype of the type III endothelial cells is a spindle-shaped monolayer with vacuoles, and the diameter of these cells is about 30 m [16] . Cells were grown in DMEM/F-12 medium containing 5% fetal calf serum on plates precoated with 1% collagen type I. Experiments were performed on confluent cultures in 48-well plates (Corning, Corning, NY), and the cells were from passages 14-17. Before addition of the various compounds, cells were transferred to serum-free medium containing 0.1% BSA, insulin (2 g/ml), transferrin (5 g/ml), sodium selenite (5 ng/ml), and arachidonic acid (10 M). Cells were then incubated in medium only, or in medium containing Ang I (10 Ϫ9 M) and captopril (an ACE inhibitor, 10 Ϫ5 M), P 4 (10 Ϫ6 M), E 2 (10 Ϫ11 M), LH (10 ng/ml), PGF 2␣ (10 Ϫ7 M), PGE 2 (10 Ϫ7 M), atrial natriuretic peptide (10 Ϫ7 M), ET-1 (10 Ϫ7 M) OT (10 Ϫ7 M), VEGF (10 ng/ml), bFGF (10 ng/ml), or a combination of these factors for 24 h at 37ЊC in a CO 2 incubator (5% CO 2 and 95% air). At least 3 experiments were performed, with each concentration of agents tested with 3 replications/experiment.
Hormone Determination
Concentration of Ang II in the medium was determined with the second-antibody enzyme immunoassay (EIA). We used undiluted medium for the Ang II EIA. The EIA for Ang II [7] used a rabbit anti-human Ang II antibody provided by Dr. K. Wakabayashi, Gunma University, Japan. The standard curve of Ang II ranged from 2.4 to 2500 pg/ ml, and the ED 50 of the assay was 100 pg/ml. The intraand interassay coefficients of variation were on average 6.4% and 8.7%, respectively. The cross-reactivity of Ang II antibody with Ang I in the medium was 1%.
Collection of Bovine CL
Ovaries with CL were collected from German Fleckvieh cows at a local abattoir within 10-20 min after exsanguination. The luteal stage was classified to early, mid, and late stages by macroscopic observation of the ovary as described previously [17] . After determination of the stages, CL were separated immediately from the ovaries, frozen rapidly in liquid nitrogen, and stored at Ϫ80ЊC until processed.
Tissue Extraction of Ang II
Tissue (1 g wet weight) was transferred into 10 ml of an acidic buffer (pH 2.8). This buffer contains 205 l orthophosphoric acid, 2.264 g NaH 2 PO 4 ϫH 2 O, 1.86 g EDTA, 7.01 g NaCl, 0.2 g NaN 3 , 2.0 g BSA, 1 ml Triton X-100, and one Complete tablet per liter. These tablets contain both reversible and irreversible protease inhibitors, and inhibit a broad spectrum of serine, cysteine, and metalloproteases as well as calpains. The mixture was homogenized in an ice bath with Ultra Turrax equipment (Janke and Kunkel, Staufen, Germany). The tissue was homogenized with 15-sec bursts of shredding at maximum speed, separated by 45-sec intervals of cooling. The homogenate was subsequently centrifuged at 2000 ϫ g for 15 min at 4ЊC. The supernatant (an aliquot of 1 ml) was transferred to a small encapped Octyl column (C 8 : Ci-C 8 H 17 ) from Amersham-Pharmacia (Freiburg, Germany). The column was calibrated with 3 ml methanol (MeOH) and 3 ml distilled water, and Ang II was eluted with 4 ml acetonitrile (10% v:v, acidified with 0.1% trichloracetic acid). The eluate was evaporated and diluted with assay buffer for Ang II EIA. The recovery rate of Ang II with this process was 42%.
RNA Isolation
Total RNA from bovine CL was isolated by the singlestep method of Chomczynski and Sacchi [18] using Trizol reagent. Total RNA from endothelial cells was isolated using the NucleoSpin RNA Kit (Macherey-Nagel, Düren, Germany). Finally, RNA was dissolved in water and spectroscopically quantified at 260 nm. To verify the quantity and quality of RNA, aliquots were electrophoresed on a 1% denaturing agarose gel that was stained with ethidium bromide.
Reverse Transcription (RT)-Polymerase Chain Reaction (PCR)
Four micrograms of total RNA were used to generate single-strand cDNA in a 60-l reaction mixture as described [19] . Conditions for enzymatic amplification were optimized for each PCR as follows: the AT1R and AT2R PCRs contained 10 mM Tris-HCl (pH 8.8), 50 mM KCl, 1.5 mM MgCl 2 , 0.1% Triton X-100, 0.6 M of each primer, and 0.5 U of the thermostable polymerase PrimeZyme to 5 l cDNA (final volume 25 l). The ubiquitin PCR was performed under the same conditions as those for AT1R and AT2R, but a higher concentration of primer (1.5 M) was used. On the basis of a detailed optimization of temperature, amplification of AT1R and AT2R consisted of one denaturation step at 94ЊC for 2 min, followed by 35 cycles at 94ЊC for 30 sec and at 64ЊC (AT1R) or 68ЊC (AT2R) for 45 sec. One additional elongation step was carried out at 72ЊC for 2 min. Amplification of the housekeeping gene consisted of one denaturation step at 94ЊC for 2 min; 22 cycles of 94ЊC for 45 sec, at 55ЊC for 45 sec, and at 72ЊC for 45 sec; and one additional elongation step at 72ЊC for 2 min.
To determine the optimal quantity of reverse transcript needed for PCR and to verify that the cDNA product was dependent on the amount of transcript used, varying quantities of transcript template were used in the PCR reaction. The RT product from 3 l was in the linear range for these amounts and produced a visible band. To exclude the possibility of amplification of genomic DNA, all experiments included reactions in which the RT enzyme or cDNA template was omitted. As a negative control, water was used instead of RNA for the RT-PCR to exclude any contamination from buffers and tubes. The primers were designed . Cells were incubated in media for the indicated times, the media at the end of the incubation period were collected, and Ang II was determined by EIA. Ang II concentrations shown are validated values as the antibody used in the EIA had no cross-reactivity with Ang I. Ang II production was not detected without addition of Ang I. Data are expressed as means Ϯ SEM of three experiments. a and b, P Ͻ 0.05 during the same time period.
to encode the bovine sequences by using the EMBL database, or were used as described elsewhere and commercially synthesized (Amersham-Pharmacia). The primers were chosen using the ''Husar'' online software package in Heidelberg (http://genome.dkfz-heidelberg.de). As a negative control, water was used instead of RNA for the RT-PCR to exclude any contamination from buffers and tubes. The primers were as follows: AT1R forward 5Ј-GAAGCT-GGAAGACAACCA-3Ј and reverse 5Ј-TCCCAAAGTA-GACCTGCC-3Ј; AT2R forward 5Ј-CACCACCACCATC-TGCTT-3Ј and reverse 5Ј-TCTGAACTGGGGTGCAGA-3Ј (335 bp; corresponding to bases 138-472 of the ovine mRNA partial sequence: EMBL no. S81979); ubiquitin forward 5Ј-ATGCAGATCTTTGTGAAGAC-3Ј and reverse 5Ј-CTTCTGGATGTTGTAGTC-3Ј (189 bp) [20] .
Aliquots of the PCR reaction products (5 l) were added to 1 l bromphenol blue glycerin and fractionated by electrophoresis through a 1.5% agarose gel containing ethidium bromide in a constant 60-V field. To determine the length of the RT-PCR products, a mass ladder and 100-bp marker were used. The resultant band intensities were scanned by a video documentation system (Amersham-Pharmacia) and analyzed with the Image Master 1D program (AmershamPharmacia). Each PCR product was confirmed by use of direct PCR product sequencing (TopLab, Munich, Germany).
Statistical Analysis
All experiments were repeated 3-13 times. Data are presented as means Ϯ SEM. Means were analyzed by ANOVA followed by Fisher's protected least-significant difference test. Differences were considered significant at P Ͻ 0.05.
RESULTS
Dose-Dependent Production of Ang II from Ang I
As shown in Table 1 , conversion of Ang I to Ang II increased dose-dependently with the addition of Ang I (P Ͻ 0.05). Ang II production was not detected without addition of Ang I, or in the presence of 10 Ϫ10 and 10 Ϫ11 M Ang I in the MVE culture. The conversion of 10 Ϫ9 M Ang I to Ang II was estimated at about 21%. At this Ang I concentration, the cross-reactivity of Ang II antibody with Ang I in the medium was 1%. On the basis of these results, for further experiments, a dose of 10 Ϫ9 M was selected for Ang I as a precursor of Ang II.
Time-Dependent Production of Ang II
The production of Ang II from Ang I (10 Ϫ9 M) timedependently rose for 24 h (Fig. 1) . Addition of captopril (ACE inhibitor, 10 Ϫ5 M) to the MVE cultures significantly inhibited the Ang II conversion from Ang I from 6 h to 24 h (P Ͻ 0.05; Fig. 1 ).
Effects of VEGF and bFGF on the Production of Ang II
The effects of VEGF (10 ng/ml) and bFGF (10 ng/ml) on Ang II production by bovine MVE are shown in Figure  2 . Addition of E 2 (10 Ϫ11 M), P 4 (10 Ϫ6 M), VEGF, or bFGF alone and in combination with P 4 to the MVE cultures had no effect on the production of Ang II (Fig. 2) . However, addition of E 2 ϩVEGF or E 2 ϩbFGF to the MVE cultures increased the Ang II production (P Ͻ 0.05; Fig. 2 ). Addition of LH (10 ng/ml), PGF 2␣ (10 Ϫ7 M), PGE 2 (10 Ϫ7 M), atrial natriuretic peptide (10 Ϫ7 M), ET-1 (10 Ϫ7 M), or OT (10 Ϫ7 M) alone had no effect (data not shown).
Ang II Production and mRNA Expression for AT1R and AT2R in Bovine MVE
Addition of captopril (10 Ϫ5 M) decreased Ang II production by bovine MVE cultured in medium containing Ang I (10 Ϫ9 M) when compared with basal production (P Ͻ 0.05; Fig. 3a) . Under these conditions, specific transcription for AT1R and AT2R were detected in bovine MVE. AT1R and AT2R mRNA expression in the MVE did not change with captopril treatment despite its clear effect on Ang II production (Fig. 3, b and c) .
AT1R and AT2R mRNA Expression and Ang II Peptide Concentration in Bovine CL at Different Luteal Stages of the Estrous Cycle
Specific transcripts for AT1R and AT2R were detected in bovine CL. To confirm the integrity of the mRNA templates and RT-PCR protocol, the housekeeping gene ubiquitin was examined in all samples. A representative sample for the ubiquitin RT-PCR products (189ϩ417 bp) is shown in Figure 4a . The relative signal intensities for AT1R and AT2R PCR products were assessed after correction based on the ubiquitin signal intensities.
A typical example of the expressions of AT1R and AT2R mRNAs in the CL is shown in Figure 4b . Ang II tissue FIG. 2 . Ang II production by bovine MVE cultured in medium containing Ang I (10 Ϫ9 M) only as a control (cont), and in the presence of E 2 (10 Ϫ11 M), P 4 (10 Ϫ6 M), VEGF (10 ng/ml), or bFGF (10 ng/ml), and their combination with P 4 or E 2 . Cells were incubated in media for 24 h, the media at the end of the incubation period were collected, and Ang II was determined by EIA. Ang II production was not detected without addition of Ang I. Data are expressed as means Ϯ SEM of three experiments. a and b, P Ͻ 0.05. levels and the mRNAs for AT1R and AT2R in the early, mid, and late luteal phases in the CL are shown in Figure  5 . There were no significant changes in Ang II tissue concentration and AT1R mRNA expression during the estrous cycle (Fig. 5, a and b) . In contrast, AT2R mRNA expression decreased during the midluteal phase (P Ͻ 0.05) and increased again to the highest level during the late luteal phase (P Ͻ 0.05; Fig. 5c ).
FIG. 3. Effects of control medium (without
DISCUSSION
The present results indicate the cell capacity to convert Ang II from the precursor Ang I in cultures of MVE isolated from the bovine developing CL. Ang II production was not detected without addition of Ang I. Ang II secretion was inhibited by the ACE inhibitor captopril, indicating that the MVE in bovine developing CL are a source of ACE activity. Actually, it is known that ACE is located in bovine pulmonary artery endothelial cells [10] . Furthermore, Ang II production increased in a time-dependent manner in the presence of Ang I. The data show that the ACE activity maintained a linearity over 24 h. Therefore, the findings suggest that the operation of RAS in the luteal MVE is indispensable for obtaining precursor Ang I in the bovine CL.
The combination of E 2 ϩVEGF and E 2 ϩbFGF in the MVE cultures increased Ang II production in this study. VEGF [21] and bFGF [22] are known to be strong angiogenic factors. Basic FGF mRNA expression is stimulated dose-dependently by Ang II in bovine luteal cells [12] . It has also been demonstrated that Ang II induces neovascularization in the eyes of rabbits [23] and stimulates the growth of bovine aortic endothelial cells [13] . In addition, it should be noted that in the present study these stimulations required the presence of E 2 . Low concentrations of E 2 have been shown to be an important regulator of bovine capillary endothelial cell adhesion, proliferation, and capillary-like tube formation [24] . Furthermore, it has been shown that VEGF may modulate estrogen-mediated capillary endothelial cell proliferation, angiogenic growth, and differentiation [24, 25] . Thus, these findings suggest that VEGF and bFGF together with E 2 may accelerate Ang II production in MVE, which may ensure the cascade mechanisms of angiogenesis during CL development. In contrast, P 4 in combination with VEGF or bFGF is inactive.
In the in vitro MDS of luteal explants, Ang II stimulated P 4 release in the early CL [26] but decreased P 4 release in the midluteal CL [7] . Additionally, Ang II concentrations in the perfusate fractions were higher during the early-luteal phase (9.2 pg/ml) as compared with those of the midluteal phase (3.9 pg/ml) [26] . These data indicate that intraluteal production of Ang II is more active during the early-luteal phase when angiogenesis is mostly active, and suggest that Ang II may support both angiogenesis and steroidogenesis during CL development.
We previously demonstrated that Ang II regulates release of P 4 , OT, and ET-1 in the bovine CL using an in vitro MDS [7] . In cultured bovine luteal cells, Stirling et al. [12] have also shown that Ang II decreases P 4 production supported by LH, and this effect was blocked by Ang II receptor antagonist. These results suggest that Ang II directly acts on both luteal and endothelial cells via Ang II receptors, because P 4 and OT are secreted by luteal cells [27] , whereas ET-1 is secreted by endothelial cells [28] . Contrary to this suggestion, however, it has been reported that bovine luteal cells do not possess significant amounts of binding sites for Ang II [6] . In the present series of experiments, we demonstrated AT1R and AT2R mRNA expression in the bovine CL at different stages of the estrous cycle and in the MVE isolated from the bovine developing CL. These results provide the first evidence for the expression of Ang II receptors mRNA in the bovine CL. However, we could not analyze the expression of mRNA for AT1R and AT2R in purified luteal cells apart from endothelial cells in the present experiment. Thus, to evaluate the possible crosstalk between different cell types by Ang II in the CL, the exact localization of ATRs in the CL must be clarified in future studies.
The expression of AT2R mRNA in the CL was lowest in the midluteal CL and highest in the late-luteal CL. However, the amount of Ang II production did not affect the expression of Ang II receptors mRNA in cultured MVE. Thus, the mechanism that down-and up-regulates AT2R in the CL may not be attributable to Ang II itself.
In the MDS study using the midluteal CL in vitro, PGF 2␣ enhanced the secretion of Ang II, and Ang II together with PGF 2␣ showed the maximal effect in P 4 suppression [7] . In the present MVE study, however, PGF 2␣ alone had no effect on the Ang II production in culture. As the expression of mRNA for PGF receptor was found in both luteal cells and MVE in the bovine CL [29] , the observed action of PGF 2␣ on Ang II production may directly occur on luteal cells, but not on MVE. This possibility that luteal cells also have ACE activity may be supported by the findings that bovine theca cells produce prorennin and release renin, and that this local RAS is stimulated by LH in culture [30] . Therefore, luteinized theca cells (small luteal cells) may also have a local RAS that is regulated differently from the RAS of MVE. Consequently, a complex interaction of RAS in both luteal cells and MVE probably controls local production and action of Ang II in the CL. These mechanisms appear to involve a pronounced vasoconstriction of arterioles, which should be induced by ET-1 [31] and possibly Ang II [32] during the first stage of luteolysis. At the same time, the increased secretion of Ang II may inhibit the P 4 secretion from luteal cells that directly relates to functional luteolysis. Clearly, the concept requires further detailed studies on luteal cells and in vivo observations.
In conclusion, we have confirmed that Ang II is generated from Ang I in MVE isolated from the bovine developing CL, indicating that MVE have ACE activity. In addition, mRNA expression for Ang II receptors was detected in bovine CL and in luteal MVE. These results suggest that Ang II is produced, at least in part, by action of a local RAS on MVE in the bovine CL, and that this peptide may be involved in the regulation of luteal function during development and in synergism with ET-1 during luteolysis.
